Azenta enters the post-earnings week with one of the sharpest short-interest buildups in its recent history — and the stock has barely flinched.
Short sellers have been piling into AZTA at a pace that stands out even in a volatile tape. Short interest as a percentage of free float has climbed from roughly 10.5% in early April to 15.5% today — a near-50% increase in just four weeks. The move is not a one-day spike. It has been a steady, deliberate accumulation, with the shorted float rising through each week of April and into May. The ORTEX short score now reads 69.97 out of 100, its highest level in the 10-day window, and has drifted consistently higher since mid-April. Days to cover from the most recent FINRA settlement stands at 6.2, meaning it would take more than a week of average volume for shorts to fully unwind. That is meaningful friction in a name trading at $24.61.
The borrowing market tells a more nuanced story. Availability is not particularly tight — the lending pool remains well-supplied, and cost to borrow is just 0.47%, down about 6% over the past week and tracking near multi-month lows. That combination — heavy short interest alongside easy, cheap borrow — suggests shorts are not under pressure. They can hold positions cheaply and comfortably. Availability has been running near its 12-month peak as a proportion of existing short interest, meaning there is no shortage of supply for new shorts either. Options positioning reinforces the calm. The put/call ratio is 0.19, essentially flat with its 20-day average of 0.20 and well below the 52-week high of 7.1. Options traders are not paying up for downside protection. That divergence — heavy short positioning, relaxed options market — is the central tension this week.
The analyst community is more constructive than the short book implies, though the direction of travel has been cautious. The mean price target is $34, roughly 38% above current levels, and recent ratings from Evercore ISI, Needham, and Jefferies have maintained buy-equivalent ratings. Evercore cut its target to $35 in early April from $45, a meaningful step down, while Needham has held firm at $44. Those cuts point to genuine macro concern rather than a fundamental breakdown — the bull case rests on Azenta's sample management and multiomics franchise, with M&A optionality as a sweetener. Bears counter that the stock has been trading at a premium and that end-market headwinds in life sciences tools are not yet fully in the price. EPS momentum is a relative bright spot — the 30-day and 90-day momentum factors score in the 84th and 74th percentiles respectively — suggesting estimates have been moving in the right direction, even if the EPS surprise rank itself is near the bottom. The P/E multiple of 27.5x and EV/EBITDA of 7.0x reflect a market that is paying a modest growth premium on a story still in transition.
On the institutional side, Conestoga Capital Advisors added roughly 1.5 million shares in Q1, a significant new position by any measure, lifting their stake to 6.2% of the company. Congress Asset Management added 860,000 shares in the same period, and Massachusetts Financial Services established a fresh position of 1.1 million shares. BlackRock and Vanguard both added modestly. That institutional accumulation into Q1 — while the short book was simultaneously building through April — sets up an interesting divergence between long-term buyers and tactical shorts, both active in the same name at nearly the same time.
What to watch next is whether the earnings release dated today (May 6) shakes out either side. With short interest at a multi-month high, cheap borrow meaning no forced covering, and institutional longs having built meaningful positions through Q1, the next few sessions will reveal whether the short buildup was a well-timed fundamental bet or an overextended position walking into a catalyst-driven squeeze.
See the live data behind this article on ORTEX.
Open AZTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
